Lucía Trilla-Fuertes
Has grant
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Recent Grants
Grant: Close
Doctorado Industrial
Open Date: 2016-10-01
Close Date:
Grant: Close
EPIC-XS-420: Seeking of therapeutic targets in high-risk patients of anal squamous cell carcinoma
Open Date:
Close Date:
Articles (10)
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Colorectal cancer (CRC) is a molecular and clinically heterogeneous disease. In 2015, the Colorectal Cancer Subtyping Consortium classified CRC into four consensus molecular subtypes (CMS), but these CMS have had little impact on clinical practice. The purpose of this study is to deepen the molecular characterization of CRC. A novel approach, based on probabilistic graphical models (PGM) and sparse k-means–consensus cluster layer analyses, was applied in order to functionally characterize CRC tumors. First, PGM was used to functionally characterize CRC, and then sparse k-means–consensus cluster was used to explore layers of biological information and establish classifications. To this aim, gene expression and clinical data of 805 CRC samples from three databases were analyzed. Three different layers based on biological features were identified: adhesion, immune, and molecular. The adhesion layer divided patients into high and low adhesion groups, with prognostic value. The immune layer divided patients into immune-high and immune-low groups, according to the expression of immune-related genes. The molecular layer established four molecular groups related to stem cells, metabolism, the Wnt signaling pathway, and extracellular functions. Immune-high patients, with higher expression of immune-related genes and genes involved in the viral mimicry response, may benefit from immunotherapy and viral mimicry-related therapies. Additionally, several possible therapeutic targets have been identified in each molecular group. Therefore, this improved CRC classification could be useful in searching for new therapeutic targets and specific therapeutic strategies in CRC disease.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Collaborators (5)
Alberto Munoz
Research Professor
Spanish National Research Council (CSIC)
Antje Dittmann
ETH Zürich
Francisco Jose Roig Molina
Associate Professor
Universidad San Jorge
David Hardisson
Full Professor (Catedrático)
Universidad Autónoma de Madrid
José M. Sempere
Associate Professor
Universitat Politècnica de València
Make your next move.
Prepare your application
Review drafts before you send them.